Navigation Links
Anti-tumor necrosis factor treatment does not increase cancer Risk in RA patients
Date:10/28/2009

A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy. The research team, led by Johan Askling, M.D., Ph.D., from Karolinska University Hospital in Stockholm, Sweden assessed the short-term and medium-term cancer risk for RA patients using anti-TNF therapies: infliximab, adalimumab, and etanercept. Details of the study appear in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology published by Wiley-Blackwell.

TNF is a cytokine (substance secreted by immune system cells) that regulates the body's immune system and is involved in inflammation. TNF inhibitors (or TNF blockers) are a class of therapies used to reduce inflammation in chronic inflammation such as RA. The common immunosuppressant drugs and those included in the study are Remicade, HumiraTM, and Enbrel. As these therapies are used to treat chronic inflammatory illnesses, the long-term inhibition of TNF raises concerns for increased risk of infections and cancer.

This study, one of the largest and longest population-based assessments of cancer risks associated with immunosuppressive therapy, included data from several Swedish databases including the Biologics Register, the Cancer Register, and the Early RA Register. Researchers identified and analyzed data from 6,366 patients who started anti-TNF therapy between January 1999 and July 2006. Data from patients using TNF inhibitors was compared with other groups of RA patients61,160 not taking medication, 4015 using methotrexate (the gold standard in RA treatment) and 4,015 taking combinations of disease-modifying anti-rheumatic drugs (other than TNF inhibitors).

Results show there were 240 first primary cancers diagnosed during the 25,693 person-years of follow-up in the patients using anti-TNF therapy who had no histor
'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Page: 1 2

Related medicine news :

1. CD200 stifles anti-tumor immunity
2. A new light on the anti-tumor mechanisms of Scutellaria barbata
3. Mersanas Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
4. Short-term stress enhances anti-tumor activity in mice, Stanford study shows
5. Massive necrosis after trans-catheter treatment is more common in the presence of tumor capsule
6. Popular osteoporosis drugs triple risk of bone necrosis
7. Link between treating osteoporosis with bisphosphonates and incidence of bone necrosis examined
8. Effect of tumor necrosis factor a inhibitors on heart failure risk in RA Patients
9. USC dentist links Fosomax-type drugs to jaw necrosis
10. Orthopedic Surgeon Dr. Marc W. Hungerford, a Leading Expert in Field of Avascular Necrosis, Now at Baltimore's Mercy Medical Center
11. Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... If you or a loved one ... treatment may be a challenge. Fortunately, an inventor from ... is designed to improve the experience. , He developed ... having to remove, tear or reposition their clothing. Furthermore, ... their dignity. At the same time, it safeguards their ...
(Date:9/23/2014)... been shown to be a driving force behind ... develops due to chronic inflammation caused by conditions ... relatively few effective treatment options. Now, scientists at ... for the first time in preclinical studies that ... astrocyte elevated gene-1 (AEG-1) halts the development and ...
(Date:9/23/2014)... Becker's Hospital Review has published ... Hospitals and Health Systems With Great Orthopedic Programs." ... the list have orthopedic surgery departments, programs or ... reputable sources. Exceptional orthopedic departments include physicians who ... and treat professional athletes. , This is the ...
(Date:9/23/2014)... the curve of oxygen desaturation" (AUC Desat ) may ... levels during procedures using sedation, according to a study ... AUC Desat provides information not only whether blood ... duration, and rate of episodes of oxygen desaturation. ... of Cincinnati and colleagues reports on the development of ...
(Date:9/23/2014)... Contrary to what is often assumed about single parents, ... from The Kinsey Institute has found that single parents ... active as often as singles without children -- and ... The study, "Dating and Sexual Behavior Among Single Parents ... online in the Journal of Sex Research ...
Breaking Medicine News(10 mins):Health News:Apparel for Dialysis Patients Invented by InventHelp Client (CBA-2492) 2Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:125 Hospitals With Great Orthopedic Programs 2Health News:125 Hospitals With Great Orthopedic Programs 3Health News:125 Hospitals With Great Orthopedic Programs 4Health News:125 Hospitals With Great Orthopedic Programs 5Health News:New measure provides more data on oxygen levels during sedation 2Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2
... WASHINGTON, Aug. 9 SEIU ... wherever they occur. We are ... been raised concerning SEIU Local ... Union, and will take any ...
... fade after first injection, so second shot now recommended , , ... chickenpox was introduced in the United States in 1995, medical ... single injection about the time of a child,s first birthday ... so. They,ve found that the protection from a single immunization ...
... Responding to increased concerns about the health hazards ... employed the use of the Mini C-Arm throughout ... week are bringing this advanced technology to their ... patient care, Nighttime Care Centers have introduced the ...
... of Miley Cyrus and,the Jonas Brothers will have more ... artists take the stage with other performers at Disney,s,Concert ... programs at City of Hope. It will be held ... Tickets for the concert will,be available Saturday, August 16 ...
... PD-Rx Pharmaceuticals,Inc., a publicly held corporation, (Pink Sheets: ... of all of its outstanding Preferred "A",stock., ... Cumulative,Convertible Stock representing One Hundred and Sixty Five ... Inc. The,stock call represents PD-Rx,s position to improve ...
... Aug. 8 /PRNewswire/ - IntelliPharmaCeutics is pleased to,provide ... press release to,the Company, include IntelliPharmaCeutics Ltd. and ... been very active with drug development work at ... Toronto, Canada. We,presently have 34 staff employed full-time ...
Cached Medicine News:Health News:Chickenpox Protection: Get That Booster 2Health News:Chickenpox Protection: Get That Booster 3Health News:Nighttime Care Centers Introduce Mini C-Arm Mobile X-Ray Technology to Anne Arundel County 2Health News:Nighttime Care Centers Introduce Mini C-Arm Mobile X-Ray Technology to Anne Arundel County 3Health News:The Walt Disney Company Is Presenting Miley Cyrus, Jonas Brothers and Demi Lovato in a Special Concert to Benefit City of Hope on September 14 2Health News:The Walt Disney Company Is Presenting Miley Cyrus, Jonas Brothers and Demi Lovato in a Special Concert to Benefit City of Hope on September 14 3Health News:PD-Rx Completes Call for Preferred A Stock 2Health News:IntelliPharmaCeutics Provides Update on Activities 2Health News:IntelliPharmaCeutics Provides Update on Activities 3Health News:IntelliPharmaCeutics Provides Update on Activities 4
(Date:9/23/2014)... , Sept. 23, 2014  Medela announced today ... Biomedical Company (ABC), assigning Medela as the exclusive distributor ... known as the Medela Enteral Feeding Pump. Through this ... help NICU parents and healthcare professionals by offering a ... Medela Enteral Feeding Pump is integral to the delivery ...
(Date:9/23/2014)... Sept. 23, 2014 A case report and ... SynCardia temporary Total Artificial Heart into a patient with ... were reversed, along with other abnormalities. ... the SynCardia Total Artificial Heart to treat a patient ... and video in the Journal of Visualized Experiments show ...
(Date:9/23/2014)... September 23, 2014 BerGenBio ... company, today announces it has been granted a ... Award from the UK,s Wellcome Trust to develop ... novel cancer target. The Wellcome Trust ... fund especially promising, innovative new therapeutic concepts through ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3
... SYDNEY, Sept. 15 HeartWare International, Inc. (Nasdaq: ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... CEO Doug Godshall is scheduled to make an investor ... on Tuesday, September 21, at 12:30 pm EDT.  The ...
... Md., Sept. 15 The U.S. Food and Drug ... recommendations for Valcyte (valganciclovir) oral tablets and solution used ... transplant. The update is intended to prevent drug overdosing ... area, and very low serum creatinine. The revised dosing ...
Cached Medicine Technology:HeartWare to Present at the UBS 2010 Global Life Sciences Conference 2FDA Issues New Dosing Guide for Children Using Valcyte 2
... for the Humphrey Field Analyzer, SITA ... shows less inter-test variability than Full ... of reproducibility as Full Threshold SWAP. ... with the earlier glaucoma damage detected ...
... you can trust its capabilities will ... cataract, and glaucoma therapy in one ... is the optimal system for photocoagulation, ... iridotomy. The push of a button ...
... The VISUCAM non-mydriatic ... quality and simplicity of ... big enough to set ... photography, it features a ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
Medicine Products: